RESEARCH ARTICLE

Prediction of the Chemoreflex Gain by Common Clinical Variables in Heart Failure

Gianluca Mirizzi1 *, Alberto Giannoni1, Andrea Ripoli1, Giovanni Iudice1, Francesca Bramanti1, Michele Emdin1,2, Claudio Passino1,2

1 Department of Cardiology and Cardiovascular Medicine, Fondazione Toscana G. Monasterio, Pisa, Italy, 2 Scuola Superiore Sant'Anna, Pisa, Italy

* gianlucamiri@gmail.com

Abstract

Background
Peripheral and central chemoreflex sensitivity, assessed by the hypoxic or hypercapnic ventilatory response (HVR and HCVR, respectively), is enhanced in heart failure (HF) patients, is involved in the pathophysiology of the disease, and is under investigation as a potential therapeutic target. Chemoreflex sensitivity assessment is however demanding and, therefore, not easily applicable in the clinical setting. We aimed at evaluating whether common clinical variables, broadly obtained by routine clinical and instrumental evaluation, could predict increased HVR and HCVR.

Methods and results
191 patients with systolic HF (left ventricular ejection fraction—LVEF—<50%) underwent chemoreflex assessment by rebreathing technique to assess HVR and HCVR. All patients underwent clinical and neurohormonal evaluation, comprising: echocardiogram, cardiopulmonary exercise test (CPET), daytime cardiorespiratory monitoring for breathing pattern evaluation. Regarding HVR, multivariate penalized logistic regression, Bayesian Model Averaging (BMA) logistic regression and random forest analysis identified, as predictors, the presence of periodic breathing and increased slope of the relation between ventilation and carbon dioxide production (VE/VCO2) during exercise. Again, the above-mentioned statistical tools identified as HCVR predictors plasma levels of N-terminal fragment of proBNP and VE/VCO2 slope.

Conclusions
In HF patients, the simple assessment of breathing pattern, alongside with ventilatory efficiency during exercise and natriuretic peptides levels identifies a subset of patients presenting with increased chemoreflex sensitivity to either hypoxia or hypercapnia.
Introduction

Although modern therapies have improved the natural history of chronic heart failure (HF), mainly by tackling neurohormonal activation, the prognosis of HF is dismal [1,2,3] justifying the search for novel therapeutic targets in HF.

Chemoreflex sensitivity (CS) represents a major determinant of neurohormonal imbalance in HF, being associated with reduced baroreflex sensitivity [4,5], heightened sympathetic outflow and periodic breathing (PB) [6,5,7]. Far from being an innocent bystander, CS has been acknowledged as an independent prognosticator in HF, mainly due to a detrimental effect on the arrhythmic profile leading to cardiac mortality [8,9]. Specifically, CS impacted on prognosis mainly by increasing arrhythmic events and cardiac mortality, especially when both CS to hypoxia and hypercapnia were heightened (four-years survival 49%) compared to those with normal CS (survival 100%) [9].

Nowadays, a chemoreflex modulation strategy is plausible [10], according to a growing number of animal studies [11,12,13] demonstrating its feasibility and benefits. Indeed, in a ischaemic HF model in rats, carotid body denervation reduced the central pre-sympathetic neuronal activation, normalized indexes of sympathetic outflow and baroreflex sensitivity, and reduced the incidence of apnoea; there was also a time-dependent reduction in cardiac remodelling, deterioration of left ventricle ejection fraction, and cardiac arrhythmias; these modifications, most importantly, led to an amelioration in survival [13]. The feasibility of carotid body ablation and its autonomic effects in humans were recently confirmed by a pilot trial in a patient with chronic heart failure [14]. Hence, the possibility of feedback reflex modulation is in sight and the need of simple diagnostic tools for their evaluation is pressing.

CS is measured by specific tests, assessing the ventilatory response to either hypoxia or hypercapnia, in order to calculate the hypoxic ventilatory response (HVR) and hypercapnic ventilatory response (HCVR), respectively [15]. However, several limitations (need of dedicated instrumentations, physician supervision, patients’ discomfort) have hampered its clinical spread, which is currently limited to the research environment. However, in light of the previous consideration, it is clear that we need to implement on the clinical ground the evaluation of feedback control for a better risk stratification and follow-up.

Therefore, we sought to evaluate whether common clinical variables, broadly obtained by routine clinical and instrumental evaluation, could predict the presence of increased CS to hypoxia and hypercapnia in a population of systolic HF patients.

Materials and Methods

From 2003 to 2011, we identified 191 consecutive HF patients from our outpatient clinic with echocardiographic evidence of impaired left ventricular systolic function (LVEF <50%) excluding those with: NYHA class IV, acute coronary syndrome within 6 months before examination, severe renal dysfunction (i.e. creatinine clearance < 35 ml/min), pulmonary disease (vital capacity and total lung capacity < 50% of predicted value; FEV1 [forced expiratory volume in 1 s] <50% of predicted value; and FEV1/FVC [forced vital capacity] <70%), and treatment with morphine or derivates, theophylline, oxygen, benzodiazepines or acetazolamide. All patients agreed participating in the study. They were on stable (i.e. >1 month) guideline-recommended treatment, with restriction of water/sodium intake. The study design included a standard clinical evaluation and: (1) the evaluation of chemosensitivity to hypoxia and to hypercapnia by assessing the individual HVR and HCVR; (2) neurohormonal evaluation; (3) echocardiography; (4) cardiopulmonary exercise testing (CPET) and (5) 20-min daytime polygraphy for the assessment of diurnal PB. The entire protocol was completed for each patient within 3 days.
The investigation was carried out in accordance with the Declaration of Helsinki of the World Medical Association, and has been approved by the local Ethics Committee "Comitato Etico di Area Vasta Nord-Ovest", Pisa, Italy. Patients provided written informed consent.

Chemosensitivity assessment

Chemosensitivity was assessed using the rebreathing technique [7]. Subjects were examined in standardized conditions, in a quiet room at a comfortable temperature, while seated and connected to a rebreathing circuit through a mouthpiece. They were not allowed to smoke, or drink alcohol or caffeine-containing beverages in the 12 h preceding the study. ECG, airway flow and respiratory gases were recorded continuously through a breath-by-breath gas analyser (Vmax; Sensormedics), and oxygen saturation was recorded through a pulse oximeter (SET Radical; Masimo). A 4-min baseline recording was performed during spontaneous breathing. The mean SaO2 (arterial oxygen saturation) and end-tidal CO2 during this recording were assumed as subject resting values. During the progressive isocapnic hypoxia trial (from resting SaO2 values to 70–80%, according to individual tolerance), end-tidal CO2 was maintained at a baseline value by passing a portion of the expired air into a scrubbing circuit before returning it to a 5 litre rebreathing bag. Conversely, during the progressive normoxic hypercapnic trial (from resting end-tidal CO2 values until 50 mmHg or an increase ≥10 mmHg from the basal values, according to individual tolerance), inspired arterial partial pressure of oxygen was kept at the baseline value by adding oxygen to the circuit. The two trials were performed in a random order. Examples of hypoxic normocapnic and hypercapnic normoxic trials are shown in Fig 1; examples of a normal and an altered hypoxic normocapnic trial are shown in Fig 2. All signals were digitized online (500 sample/s; National Instruments) and analysed to derive respiratory rate, breath-to-breath VT (tidal volume) and VE (minute ventilation), as well as SaO2 and end-tidal pressure of CO2. HVR was expressed by the linear regression slope between VE and SaO2 during a hypoxic-normocapnic trial, while HCVR by the linear regression slope between VE and the end-tidal CO2 during the hypercapnic-normoxic trial.

Neurohormonal evaluation, CPET, echocardiographic study, daytime cardiorespiratory recording

Plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP), catecholamine and aldosterone levels, plasma renin activity (PRA) were assayed as previously described in details [16].

Patients underwent a symptom-limited CPET on a bicycle ergometer according to a ramp protocol to achieve maximal workload in 10 ± 2 minutes (Vmax; Sensormedics). Peak oxygen consumption (peak-VO2) was determined as the highest value at peak exercise over a 20-s average; ventilatory efficiency was estimated from the VE/VCO2 slope (calculated as the slope of the linear relationship between ventilation (VE) and carbon dioxide production (VCO2) from 1 min after the beginning of the loaded exercise and the end of the isocapnic buffering period. Echocardiography was assessed according to guidelines recommendations [17]. All CPETs and echocardiographic studies were performed by physicians blinded to the chemosensitivity tests results.

As previously described [18], all subjects, while awake and spontaneously breathing in a supine position, underwent a 20-min recording including two-leads ECG, chest wall and abdominal movements by electrical inductance, oronasal airflow by CO2 signal (Cosmoplus®; Novametrics) and SaO2 (Pulse Oxymeter Pulsox-7; Minolta). Breathing pattern was evaluated visually observing the traces of nasal flow and respiratory movements; apnoea was defined as the cessation of inspiratory flow for at least 10 s, whereas hypopnoea was defined as a flow reduction (>50%) lasting 10s or more and associated with at least a 4% decrease in SaO2 [19].
Hypoxic ventilatory response

Hypercapnic ventilatory response
Apnoea and hypopnoea were considered as central or obstructive by the absence or presence of ribcage and abdominal excursions, respectively. We only considered central apnoea for our analysis.

Statistical analysis

Data are reported as mean ± standard deviation for normally distributed variables; otherwise, they are expressed as median (interquartile range, IR). A p ≤ 0.05 was considered statistically significant.

Target variables (HVR and HCVR) were dichotomized using the previously described cut-off values (increased chemosensitivity if $HVR > 0.77 \text{ L.min}^{-1}.\%\text{SaO}_2^{-1}$ and $HCVR > 0.79 \text{ L.min}^{-1}.\text{mmHg}^{-1}$) [7]. Association between target variables and covariates was studied constructing a univariate logistic regression model. Covariates that resulted significantly associated at univariate analysis (p < 0.10) were used to create a multivariate model. Owing to the high number of variables in comparison with the number of cases, we identified covariates with two distinct methods: the penalized approach and the Bayesian Model Averaging (BMA) approach [20]. This statistical approach has the clear advantage of bootstrapping multiple models by randomly selecting variables from the overall data set and assessing pre- and post-hoc probabilities of prediction to evaluate the best possible models (and predictors), according to Bayes’ principle, thus providing an adequate stability to the analysis. The output of this approach are a set of

Fig 1. Example of an hypoxic normocapnic (upper panel) and an hypercapnic normoxic (lower panel) trial. In each panel are represented the time-dependent variation of minute ventilation (VE), end-tidal carbon dioxide production (PETCO$_2$) and arterial oxygen saturation (SaO$_2$). During the hypoxic trial, SaO$_2$ diminish while PETCO$_2$ remains constant due to correction by a scrubbing circuit. During the hypercapnic trial, SaO$_2$ remains constant due to constant addition of O$_2$ to the circuit.

doi:10.1371/journal.pone.0153510.g001

Fig 2. Example of a normal (left) and abnormal (right) hypoxic normocapnic trial. In each panel are represented the time-dependent variation of minute ventilation (VE), end-tidal carbon dioxide production (PETCO$_2$) and arterial oxygen saturation (SaO$_2$). During the hypoxic trial, SaO$_2$ diminish while PETCO$_2$ remains constant due to correction by a scrubbing circuit.

doi:10.1371/journal.pone.0153510.g002
variables with a given odds ratio, thus identifying variables for which each unit increase (for example, each percent unit increase in LVEF) produces an increase or decrease of the probability of having an heightened chemoreflex sensitivity (that is, respectively, "adverse" or "protective" variables).

Parallel to this approach, in order to catch the effects of non-linear interaction between variables that are missed by conventional statistical methods, we also performed a random forest (RF) analysis, as described elsewhere [21]. Briefly, RF is an ensemble classifier build up from a set of decision trees created from a subset of training data (2/3 of original data), randomly constructed by choosing variables and samples (bootstrapping). The pre-specified rules with which the trees are assembled decides whether to split the tree (knot) or terminate it (terminal knot) at a value deemed to be the best split point for each variable. RF analysis gives the accuracy in the prediction of an observation in a sample; furthermore, it allows to rank a set of variables based on their importance in predicting the observation. For continuous variables it does not give a specific cut-off but takes into account the repercussions of the variable on the accuracy of the prediction (i.e., its increase whenever the variable is taken into account). Also for this reason, this approach has the advantage with respect to conventional statistics to avoid overfitting models and to be less sensitive to outliers. Analyses were performed using the R open-source statistical software.

Results

Patients' characteristics

Patients' general characteristics are enlisted in Table 1. Overall, HVR and HCVR were increased in 34% and 56% of patients, respectively. Patients were mainly males (83%), aged (62, SD 14 years), with balanced ischemic/non ischemic aetiology (48/52%, respectively) and with a moderate to severe LV dysfunction at echocardiography (mean left ventricular ejection fraction [LVEF] 30, SD 8%). At CPET, they showed a reduced functional capacity (mean peak VO2/kg: 13.8, SD 6.3 ml·min⁻¹·kg⁻¹) and reduced ventilatory efficiency (VE/VCO₂ slope: 37, SD 9); roughly half of the population presented with diurnal periodic breathing (PB) (48%). Neurohormonal activation was modest, with only augmented levels of plasma NT-proBNP (1117, IR 86–6851 ng/l). All patients were on optimal medical therapy. Patients with enhanced HVR as compared with those with normal chemosensitivity, showed increased ventilatory inefficiency, plasma levels of noradrenaline and gamma-glutamyltransferase (GGT), increased right ventricular (RV) dimensions. Those with increased HCVR as compared with patients with normal chemosensitivity were instead older, had lower LVEF, reached a lower maximal workload and showed increased ventilatory inefficiency; they also showed increased plasma levels of NT-proBNP, noradrenaline, GGT and greater right ventricular (RV) diameter (data not shown).

Hypoxic chemosensitivity: univariate and multivariate analysis

At univariate analysis, HVR was associated with the following 9 covariates: LVEF, RV dimension, left atrial dimensions, baseline ventilation, VE/VCO₂ slope, NT-proBNP levels, GGT levels, presence of atrial fibrillation and PB.

At multivariate penalized analysis (Table 2), HVR was associated with left atrial dimensions (odds ratio [OR] 1.012, confidence interval [C.I.] 1.005–1.148), VE/VCO₂ slope (OR 1.01, 95th C.I. 1.007–1.131), NT-proBNP levels (OR 1.007, C.I. 1.003–1.081 for each 100 units increase), GGT levels (OR 1.004, C.I. 1.001–1.153), and, more strongly with the presence of PB (OR 5.401, CI 3.712–12.655). BMA showed the same findings, with the presence of PB being the strongest variable associated with altered HVR (OR 7.91, Fig 3).
Random Forest analysis warranted an out of bag accuracy of 71%, identifying the presence of PB and increased VE/VCO₂ slope as covariate associated with HVR (Fig 4); in particular, the presence of PB conferred an increase in prediction accuracy of 3.13%.

Hypercapnic chemosensitivity: univariate and multivariate analysis

At univariate analysis, HCVR was associated with the following 8 covariates: LVEF, NYHA class, peak VO₂/kg, VE/VCO₂ slope, exercise workload, NT-proBNP levels, GGT levels and PB.

Table 1. Clinical characteristics of the HF patient population.

| Variables                        | Population n = 191 |
|----------------------------------|-------------------|
| Age, y                           | 62±14             |
| Males, %                         | 83                |
| Body Mass Index (BMI), kg/m²     | 27.0±4.2          |
| Ischemic Etiology, %             | 48                |
| NYHA Class I-II, %               | 72                |
| Periodic Breathing/ Cheyne-Stokes respiration, % | 47/24          |
| Hypoxic Ventilatory Response (HVR), I*min⁻¹*%SaO₂⁻¹ | 0.5 (0.2–1.2) |
| Hypercapnic Ventilatory Response (HCVR), I*min⁻¹*mmHg⁻¹ | 0.85 (0.2–2.1) |
| Left Ventricular Ejection Fraction (LVEF), % | 30±8             |
| End Systolic Left Ventricular Diameter, mm | 51±10          |
| End Diastolic Left Ventricular Diameter, mm | 62±8             |
| Sinus Rhythm/Atrial Fibrillation, % | 73/27            |
| Workload, W                      | 80 (40–174)       |
| Peak Oxygen Consumption, (pVO₂), ml*min⁻¹*kg⁻¹ | 13.8±6.2       |
| VE/VCO₂ slope                    | 37±9              |
| Serum Creatinine, mg/dl          | 1.2±0.4           |
| Norepinephrine, pg/ml            | 435 (141–1033)    |
| Plasma Renin Activity, ng*ml⁻¹*h⁻¹ | 1.2 (0.2–11.3)   |
| NT-proBNP, pg/ml                 | 1117 (86–6851)    |
| Plasma Aldosterone, pg/ml        | 140 (31–399)      |
| Beta-Blockers, %                 | 84                |
| ACE-inhibitors or ARBs, %        | 77                |
| Aldosterone Receptors Blockers, %| 56                |
| Diuretics, %                     | 79                |

ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blockers; NYHA, New York Class Association; NT-proBNP: N-type fragment of proBNP; VE/VCO₂ slope: slope of the relationship of CO₂ production and ventilatory response during exercise.

doi:10.1371/journal.pone.0153510.001

Random Forest analysis warranted an out of bag accuracy of 71%, identifying the presence of PB and increased VE/VCO₂ slope as covariate associated with HVR (Fig 4); in particular, the presence of PB conferred an increase in prediction accuracy of 3.13%.

Hypercapnic chemosensitivity: univariate and multivariate analysis

At univariate analysis, HCVR was associated with the following 8 covariates: LVEF, NYHA class, peak VO₂/kg, VE/VCO₂ slope, exercise workload, NT-proBNP levels, GGT levels and PB.

Table 2. Penalized multivariate analysis of HVR predictors.

| Variable                  | OR (95% I.R.)            |
|---------------------------|--------------------------|
| VE/VCO₂ slope             | 1.010 [1.007–1.131]      |
| NT-proBNP                 | 1.007 [1.003–1.081]      |
| GGT                       | 1.004 [1.001–1.153]      |
| Left atrial diameter      | 1.012 [1.005–1.148]      |
| Presence of PB            | 5.401 [3.712–12.655]     |

GGT: gamma glutamyltransferase; NT-proBNP: N-type fragment of proBNP; PB: periodic breathing; VE/VCO₂ slope: slope of the relationship of CO₂ production and ventilatory response during exercise.

doi:10.1371/journal.pone.0153510.002
At penalized multivariate analysis, HCVR was associated with LVEF (OR 0.976, 95th C.I. 0.647–0.985), VE/VCO2 slope (OR 1.028, C.I. 1.009–1.250), NT-proBNP (OR 1.009, C.I. 1.002–1.059 for each 100 units increase), GGT (OR 1.002, C.I. 1.0007–1.357), PB (OR 1.096, C.I. 1.005–1.766) (Table 3). BMA found a weak evidence for VE/VCO2 slope (OR 1.04) and NT-proBNP (OR 1.01 for each 100 units increase) (Fig 5).

Random Forest analysis warranted an out of bag accuracy of 58%, identifying the presence of NT-proBNP and VE/VCO2 slope as covariate associated with HCVR (Fig 4); in particular, the presence of NT-proBNP conferred an increase in prediction accuracy of 1.95%, while VE/VCO2 slope of 1.37%.

Discussion

In this study, we assessed the clinical predictors of altered chemosensitivity to hypoxia and hypercapnia in a cohort of systolic HF patients suggesting that chemoreflex, a critical pathophysiological determinant of HF progression and prognosis, may be predicted by using few clinical parameters easily obtainable and commonly assessed in whichever HF clinic: a blood withdrawal (NT-proBNP), a cardiopulmonary test (VE/VCO2 slope) and a short-term cardiorespiratory monitoring (diurnal PB). In fact, they correctly predicted HVR and HCVR in 70% and 60% of cases, respectively.

The clinical relevance of assessing the CS in HF

Growing evidences support the notion that increased CS to hypoxia [8] and hypercapnia [9] act as pernicious players in the HF pathophysiological background. Beyond its acknowledged role as the mechanism underlying PB [6,8,9,22], increased CS has been associated with worse symptoms, lower performance during exercise, higher sympathetic activity and increased...
These pathophysiological alterations lead to a significant increase in the risk of cardiac death and arrhythmic events in HF. In the study of Ponikowski et al [8], 3-year survival in those with heightened peripheral CS was 41% vs. 77% in those with normal one. When assessed in a well characterized and on guideline-directed medical therapy comprehensive of beta-blockers (86%) and implantable-cardioverter device/cardiac resynchronization therapy, increased CS still maintains its prognostic value, especially when both peripheral and central CS are augmented (4-year survival 49% vs. 100% in those with normal CS) [9]. It is also significant that the studies assessing the prognostic significance of altered CS to hypoxia used different methods to assess it (transient hypoxic method by Ponikowski and rebreathing technique by Giannoni); while no specific comparison between the two methods have not been

![Random forests analysis for HVR and HCVR predictors](https://doi.org/10.1371/journal.pone.0153510.g004)

**Table 3. Penalized multivariate analysis of HCVR predictors.**

| Variable              | OR (95% I.R.)          |
|-----------------------|------------------------|
| LVEF                  | 0.976 [0.647–0.985]    |
| NT-proBNP             | 1.099 [1.002–1.059]    |
| GGT                   | 1.002 [1.007–1.357]    |
| VE/VCO₂ slope         | 1.028 [1.009–1.250]    |
| Presence of PB        | 1.096 [1.095–1.766]    |

GGT: gamma-glutamyltransferase; LVEF: left ventricular ejection fraction; NT-proBNP: N-type fragment of pro-brain natriuretic peptide; PB: periodic breathing; RV: right ventricle; VE/VCO₂ slope: slope of the relationship of CO₂ production and ventilatory response during exercise.

doi:10.1371/journal.pone.0153510.t003
undertaken, the clinical significance of both might suggest that the biological phenomenon, and not the specific measure to estimate it, is of relevance for the clinician.

Animal studies have also demonstrated that CS modulation reverses the above-mentioned negative consequences and improves survival [13,24]. In fact, in an ischaemic rat model of chronic HF carotid body ablation reduced pre-sympathetic activation, overall sympathetic outflow, normalized baroreflex activation and attenuated cardiac remodelling and LEVF reduction; these translated in an increase in survival from 45 to 85%. If a beneficial prognostic effect should be confirmed in humans after the demonstration of the safety, feasibility and tolerability of carotid body surgical resection [14], this could lead to the opening of a strategy of chemoreflex modulation in HF.

The application to a broad population of these new developments requires an adequate evaluation of CS. Since now this has been hampered by the difficult spread of the chemoreflex tests, due to technical issues (need of trained physicians, time-consuming test execution and analysis) and patient discomfort, potentially making suboptimal both risk stratification and treatment approach in HF patients, especially in the fore coming new era of the feedback control therapy.

Even if the implementation of a widespread assessment of CS is still the goal to be pursued, a convenient strategy may be the identification of a set of common clinical parameters whose alteration could suggest the presence of altered CS to hypoxia or hypercapnia and prompt the evaluation by specialized laboratories which deal with respiratory derangements in HF and their diagnosis. It seems thus judicious to include as much as possible candidates with altered CS while avoiding their exclusion (i.e. prefer sensitivity to specificity); from this point of view, for example, the identification of 11% of patients (i.e., one out of ten) with PB but without increased HVR might represent a reasonable trade-off to avoid such under-diagnosis while sparing, on the other hand, chemoreflex evaluation in a consistent portion of patients (53%).

Fig 5. Bayesian Model Averaging analysis of HCVR predictors. Colour coding and acronyms same as Fig 2.

doi:10.1371/journal.pone.0153510.g005
The first clinical model for prediction of CS in HF

Since now, mathematical models [25,26,27] and clinical studies [28] have focused on the possibility to predict PB using the chemoreflex as one of the possible contributors and not as the real target, raising attention to the epiphenomenon and not to the mechanism behind it.

In this respect, to our knowledge, this is the first attempt to predict CS to both stimuli (hypoxia and hypercapnia) starting from a comprehensive and large cohort of patients fully characterized and under guideline-recommended therapy. In fact, in a small series of HF patients (n = 34) a similar approach have been recently confined to the exclusive prediction of peripheral CS, with NT-proBNP identified as the only independent predictor of HVR; however, the small number of patients recruited and the type of statistics performed limits the strength of study results [29]. The rigorous statistical model developed in this study has allowed us to identify 3 main clinical predictors of CS, namely PB, VE/VCO2 slope and NT-proBNP, with the possibility to infer the hypoxic and hypercapnic ventilatory response straight off, without actually performing any test.

In our study, only using PB and VE/VCO2 slope it is possible to closely predict HVR, with an out of bag accuracy of 71% from RF analysis. The strongest variable in this model is represented by PB, which conferred an increase in prediction accuracy of more than 3 times. This relationship has been already highlighted in several previous reports [30,31]. Normalization of peripheral CS, by administration of dihydrocodeine or exposition to hyperoxia in humans [32] and by carotid body monolateral or bilateral cryoablation in animals [24] resulted in normalization of breathing pattern. Our study supports these previous findings. Hence, in clinical practice, recognition of PB, much easier to be evaluated in respect to CS, could act as a red flag for identifying patients with altered HVR.

Our data suggest VE/VCO2 slope as another contributor in the prediction of HVR. HVR is a measure of the peripheral chemosensitivity. It is known that peripheral chemoreceptors also account for the ventilatory response to carbon dioxide increase (about 20% of the global response), so a relationship between HVR and VE/VCO2 slope is likely. Moreover, during effort the contribution of peripheral chemoreceptors may be increased [33].

VE/VCO2 slope, in fact, also allowed the prediction of the HCVR in our HF patient cohort, replicating the observation made by previous reports in HF patients [7,32]. In fact, VE/VCO2 slope might be considered another possible way of assessing the ventilatory response to CO2, with CO2 released by the working muscles and not provided from outside. It must be noted that a contributor to VE/VCO2 slope is given by increased pulmonary dead space, especially in more advanced disease states [34]; however, it was recently associated, in an HF population, to chronic obstructive pulmonary disease comorbidity [35], which we excluded as entry criterion. The emergence of VE/VCO2 as a predictor of increased chemoreflex sensitivity, despite the exclusion of dead space as a cofactor, further stresses the importance of the relation between the two parameter, not always recognized in the adequate manner.

NT-proBNP also plays a role in the prediction of HCVR, as already found in a different cohort by our group [7]. Two reasons of this observation could be made: first, in an animal study performed on pacing induced HF rabbit, a reduction of peripheral chemoreceptor perfusion by carotid occlusion similar to the one obtained with cardiac output reduction (and potentially expressed by higher level of NT-proBNP), was associated with increased peripheral chemoreceptors, which are also responsive to CO2, thus contributing to HCVR [36,37]. Second, an increase in the diastolic filling pressure (again sensed by the natriuretic peptide system) with stimulation of pulmonary J receptors, may justify a medullary-mediated augmentation of both peripheral and central chemoreceptor reflexes. Generally, NT-proBNP levels could
synthesize the multiple influences of the various axes (renin angiotensin aldosterone systems, adrenergic systems) on both peripheral and central chemoreceptors [23,38,39].

On the whole, the absolute predictive power of the model is weaker for HCVR than for HVR (predictive accuracy respectively 58 vs. 71%), likely owing to the different physiological complexity of the two reflexes. HVR relies only on the response of the peripheral chemoreceptor to O2 tension reduction, while HCVR express the response of both peripheral (20%) and central chemoreceptors (80%) to rise in CO2. The interaction between peripheral and central chemoreceptors, as well as the multiplicity of different anatomic locations and physiologic responses of central chemoreceptors [40] adds to the complexity and justifies the findings.

Study limitations
Despite the limited number of patients recruited, this is one of the largest cohorts of HF patients with complete evaluation of peripheral and central chemoreflexes. Despite the lack of control normal population, the results are consistent because of the statistical approach, that used an internal group (1/3 of the population) as learning subset and the rest of the population as testing subset. Moreover, the number of patients with altered CS is relatively high, allowing the performance of meaningful statistical analysis. Nevertheless, some patients (23%, n = 44) showed combined increased CS; we decided to evaluate this subgroup of patients singularly for CS, and not as a separate subgroup, because the number of patients could hardly permit a separate statistical evaluation of adequate consistency and the relative small number of individuals should not affect statistical output.

The population evaluated was composed exclusively of patients with systolic HF; no patients with HF and preserved ejection fraction were evaluated. Diastolic dysfunction could influence CS status acting on pulmonary J receptors and enhancing ventilatory responses. In dog models of congestive HF, inflating a balloon in the left atrium, mimicking the increases in left ventricular end-diastolic pressure encountered clinically, causes hyperventilation and increase in loop gain of the ventilatory response to CO2 [41]. It must also be recalled that in recent series of systolic HF patients, neither LVEF nor diastolic function were associated with increased pulmonary artery pressure, while were chemoreflex status and the presence of central apnoeas [42] thus highlighting the independent influences of feedback loops on hemodynamics and principally on that of the pulmonary circulation.

We choose to perform multiple multivariate statistical analysis in order to avoid the possibility of overfitting models, which cannot however be excluded. The concordance between findings of standard statistical methods and computational iterative statistics gives strength to the overall results, even if reproducibility of the sets of variables identified is an issue to be verified. Testing patients under conditions of normocapnic or normoxic conditions during respectively HVR and HCVR could provide less reliable results due to individual variability in the response to CO2 or O2. However, while this is relevant in a physiological scenario, it is less relevant in a clinical scenario like ours, because global response to hypoxia or hypercapnia is what patients with heart failure develop in their daily living, for example during cycles of apnoea; moreover, these same stimuli have been demonstrated to increase the risk of events in the same patients [9].

Conclusion and clinical perspectives
In HF patients, the assessment of breathing pattern, alongside with ventilatory efficiency during exercise and natriuretic peptides levels, helps to identify the subset of patients with increased hypoxic or hypercapnic chemosensitivity. Using these parameters in daily clinical practice may allow the identification of patients with altered CS and prompt the standard
evaluation of chemosensitivity; this approach could help widely including the chemoreflex status in the risk stratification of HF patients. This information might be used to contribute to the setup of rational follow-up strategies and to build up a tailored pharmacological/non-pharmacological approach specifically directed to the chemoreflex target.

Author Contributions
Conceived and designed the experiments: GM AG ME CP. Performed the experiments: GM AG GI FB. Analyzed the data: GM AG AR ME CP. Wrote the paper: GM AG CP.

References
1. O’Connor CM, Abraham WT, Albert NM, Clare R, Gattis Stough W, Gheorghiade M, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program To Initiate lifesaving treatMent In hospitaliZed patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2008; 156: 662–673. doi: 10.1016/j.ahj.2008.04.030 PMID: 18926148
2. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Pro- gram To Initiate lifesaving treatMent In hospitaliZed patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008; 52: 347–356. doi:10.1016/j.jacc.2008.04.028 PMID: 18652942
3. Flynn KE, Piña IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, et al. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized clinical trial. JAMA 2009; 301: 1451–1459. doi:10.1001/jama.2009.457 PMID: 19351942
4. Despas F, Lambert E, Vaccaro A, Labrunee M, Franchitto N, Lebrin M, et al. Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. J Hypertens 2012; 30: 753–760. doi:10.1097/HJH.0b013e328350136c PMID: 22241144
5. Ponikowski P, Chua TP, Piepoli M, Ondusova D, Webb-Peploe K, Harrington D, et al. Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure. Circulation 1997; 96: 2586–2584. PMID: 9359898
6. Javaheri S. A mechanism of central sleep apnea in patients with heart failure. N Engl J Med 1999; 341: 949–954. PMID: 10498490
7. Giannoni A, Emdin M, Poletti R, Bramanti F, Prontera C, Piepoli M, et al. Clinical significance of chemosen-sitivity in chronic heart failure: influence on neurohormonal derangement, Cheyne-Stokes respira-tion and arrhythmias. Clin Sci 2008; 114: 489–497. PMID: 17961123
8. Ponikowski P, Chua TP, Anker SD, Francis DP, Doehner W, Banasiak W, et al. Peripheral chemoreceptor hypersensitivity: an ominous sign in patients with chronic heart failure. Circulation 2001; 104: 544–549. PMID: 11472951
9. Giannoni A, Emdin M, Poletti R, Iudice G, Francis DP, Barsotti A, et al. Combined increased chemosen-sitivity to hypoxia and hypercapnia as a prognosticator in heart failure. J Am Coll Cardiol 2009; 53: 197519–80.
10. Paton JF, Sobotka PA, Fudim M, Engelman ZJ, Hart EC, McBryde FD, et al. The carotid body as a therapeu-tic target for the treatment of sympathetically mediated diseases. Hypertension 2013; 61: 5–13. doi:10.1161/HYPERTENSIONAHA.111.00964 PMID: 23172927
11. Moraes DJ, Bonagamba LG, Zoccal DB, Machado BH. Modulation of respiratory responses to chemoreflex activation by L-glutamate and ATP in the rostral ventrolateral medulla of awake rats. Am J Physiol Regul Integr Comp Physiol 2011; 300: R1476–86. doi:10.1152/ajpregu.00829.2010 PMID: 21411762
12. Rocha I, Brás-Rosário L, Amaparo-Barros M, Silva-Cardvalho L. Angiotensin AT1 receptor antagonist losartan and the defence reaction in the anaesthetised rat. Effect on the carotid chemoreflex. Exp Physiol 2003; 88: 309–14. PMID: 12719753
13. Del Rio R, Marcus NJ, Schultz HD. Carotid chemoreceptor ablation improves survival in heart failure: rescuing autonomic control of cardio respiratory function. J Am Coll Cardiol 2013; 62: 2422–30. doi:10:1016/j.jacc.2013.07.079 PMID: 24013058
14. Niewiński P, Janczak D, Rucinski A, Jazwiec P, Sobotka PA, Engelman ZJ, et al. Carotid body removal for treatment of chronic systolic heart failure. Int J Cardiol 2013; 168: 2506–2509. doi:10.1016/j.ijcard.2013.03.011 PMID: 23541331
15. Duffin J. Measuring the respiratory chemoreflexes in humans. Respir Physiol Neurobiol 2011; 177: 71–8. doi:10.1016/j.resp.2011.04.009 PMID: 21514404
16. Emdin M, Passino C, Prontera C, Iervasi A, Ripoli A, Masini S, et al. Cardiac natriuretic hormones, neurohormones, thyroid hormones and cytokines in normal subjects and patients with heart failure. Clin Chem Lab Med 2004; 42: 627–36 PMID: 15259379

17. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Chamber Quantification Writing Group; American Society of Echocardiography’s Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440–63 PMID: 16376782

18. Poletti R, Passino C, Giannoni A, Żyw L, Prontera C, Bramanti F, et al. Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients. Int J Cardiol 2009; 137: 47–53 doi: 10.1016/j.ijcard.2008.06.028 PMID: 18691782

19. Yamashiro Y. and Kryger M. H. Sleep in heart failure. Sleep 2013; 16: 513–523

20. Wang D, Zhang W, Bakhai A. Comparison of Bayesian model averaging and stepwise methods for model selection in logistic regression. Stat Med 2004; 23: 3451–3467. PMID: 15505893

21. Breiman L. “Random Forests”. Machine Learning 2001; 45: 5–32

22. Bradley TD, Floras JS. Sleep Apnea and Heart Failure. Part II: Central Sleep Apnea. Circulation 2003; 107: 1822–1826. PMID: 12682029

23. Yamada K, Asano H, Ueno H, Joho S, Takagawa J, Kameyama T, et al. Role of central sympathoexcitation in enhanced hypercapnic chemosensitivity in patients with heart failure. Am Heart J 2004; 148: 964–70. PMID: 15632879

24. Marcus NJ, Del Rio R, Schultz EP, Xia XH, Schultz HD. Carotid body denervation improves autonomic and cardiac function and attenuates disordered breathing in congestive heart failure. J Physiol 2014; 592: 391–408. doi: 10.1113/jphysiol.2013.266221 PMID: 24279895

25. Khoo MC. Determinants of ventilatory instability and variability. Respir Physiol 2000; 122: 167–82. PMID: 10967342

26. Francis DP, Wilsson K, Davies LC, Coats AJ, Piepoli M. Quantitative general theory for periodic breathing in chronic heart failure and its clinical implications. Circulation 2000; 102: 2214–21. PMID: 11056095

27. Manisty CH, Wilsson K, Wensel R, Whinnett ZI, Davies JE, Oldfield WL, et al. Development of respiratory control instability in heart failure: a novel approach to dissect the pathophysiological mechanisms. J Physiol 2006; 577: 387–401. PMID: 16959858

28. Sin DD, Fitzgerald F, Parker JD, Newton G, Floras JS, Bradley TD. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999; 160: 1101–6. PMID: 10508793

29. Niewinski P, Engelman ZJ, Fudim M, Tubek S, Paleczny B, Jankowska EA, et al. Clinical predictors and hemodynamic consequences of elevated peripheral chemosensitivity in optimally treated men with chronic systolic heart failure. J Card Fail 2013; 19: 408–15. doi: 10.1016/j.cardfail.2013.03.013 PMID: 23743490

30. Ponikowski P1, Anker SD, Chua TP, Francis D, Banasiak W, Poole-Wilson PA, et al. Oscillatory breathing patterns during wakefulness in patients with chronic heart failure: clinical implications and role of augmented peripheral chemosensitivity. Circulation 1999; 100: 2418–24. PMID: 10595954

31. Dempsey JA, Smith CA, Blain GM, Xie A, Gong Y, Teodorescu M. Role of central/peripheral chemoreceptors and their interdependence in the pathophysiology of sleep apnea. Adv Exp Med Biol 2012; 758: 343–9. doi: 10.1007/978-94-007-4584-1_46 PMID: 23080181

32. Blain GM, Smith CA, Henderson KS, Dempsey JA. Peripheral chemoreceptors determine the respiratory sensitivity of central chemoreceptors to CO2. J Physiol 2010; 588: 2455–71. doi: 10.1113/jphysiol.2010.187211 PMID: 20421288

33. Chua TP, Clark AL, Amadi AA, Coats AJ. Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure. J Am Coll Cardiol. 1996 Mar 1; 27(3):650–7. PMID: 8606277

34. Wasserman K, Zhang YY, Gitt A, Belardinelli R, Koike A, Lubarsky L, Agostoni PG. Lung function and exercise gas exchange in chronic heart failure. Circulation 1997; 96:2221–7. PMID: 9337193

35. Apostolo A, Laveneziana P, Palange P, Agabito C, Molle R, Popovic D, et al. Impact of chronic obstructive pulmonary disease on exercise ventilatory efficiency in heart failure. Int J Cardiol 2015; 189:134–40 doi: 10.1016/j.ijcard.2015.03.022 PMID: 25889444
36. Solin P, Roebuck T, Johns DP, Walters EH, Naughton MT. Peripheral and central ventilatory responses in central sleep apnea with and without congestive heart failure. Am J Respir Crit Care Med 2000; 162: 2194–200. PMID: 11112137

37. Ding Y, Li YL, Schultz HD. Role of blood flow in carotid body chemoreflex function in heart failure. J Physiol 2011; 589: 245–58. doi: 10.1113/jphysiol.2010.200584 PMID: 21078591

38. Li YL, Xia XH, Zheng H, Gao L, Li YF, Liu D, et al. Angiotensin II enhances carotid body chemoreflex control of sympathetic outflow in chronic heart failure rabbits. Cardiovasc Res 2006; 71: 129–38. PMID: 16650840

39. Gao L, Pan YX, Wang WZ, Li YL, Schultz HD, Zucker IH, et al. Cardiac sympathetic afferent stimulation augments the arterial chemoreceptor reflex in anesthetized rats. J Appl Physiol 2007; 102: 37–43. PMID: 16902057

40. Nattie E, Li A. Central chemoreception is a complex system function that involves multiple brain stem sites. J Appl Physiol 2009; 106: 1464–6. doi: 10.1152/japplphysiol.00112.2008 PMID: 18467549

41. Chenuel BJ, Smith CA, Skatrud JB, Henderson KS, Dempsey JA. Increased propensity for apnea in response to acute elevations in left atrial pressure during sleep in the dog. J Appl Physiol (1985). 2006 Jul; 101(1):76–83.

42. Giannoni A, Raglianti V, Mirizzi G, Taddei C, Del Franco A, Luidice G, et al. Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure. Int J Cardiol 2016; 202:200–6. doi: 10.1016/j.ijcard.2015.09.007 PMID: 2639712